Schistosoma Japonicum: Modern Tools for an Ancient Disease

Wei Hu

2004-01-01

Abstract:4but it was only in the 1970s that safe single-dose oral drugs, such as oxamniquine and praziquantel, were introduced for human therapy. 5 Progress in the war against schistosomiasis is badly needed, because the number of infected people is not decreasing and the available treatments are insufficient. Although socioeconomic progress has eliminated schistosomiasis from large areas of the world, the development of irrigation resources and population movements have spread the disease to previously non-endemic territories. Thus 200 million people are infected and 650 million are at risk. In 2002 there were 280 000 deaths from schistosomiasis. 6 No new drugs are being developed, despite the pending threat of drug resistance, and it is unlikely that an effective vaccine will become available during the next decade. 7 The infective agent is a waterborne larva (the cercaria) that penetrates intact human skin in contaminated freshwater. After penetration, the cercaria undergoes complex transformation and migration through the host tissues, until it settles in the mesenteric veins (Schistosoma mansoni and S japonicum) or in the perivesical veins (S haematobium). At this stage, the adult worms are sexually differentiated and can mate and produce eggs. About half the eggs traverse the intestinal or vesical wall and thus escape to the external environment via faeces or urine, hatch in contact with freshwater, and release a swimming larva (miracidium) that infects the intermediate host, an aquatic snail. The cercariae that emerge a month later from the snail are ready to infect humans and start the cycle again. Eggs retained in the human body are responsible for the clinical features of the disease. They accumulate in the liver or in the tissues of the urinary tract, where they elicit an immune reaction characterised by the formation of granulomas. One of the most fascinating—and harmful— features of schistosomes is their ability to survive and produce eggs for many years in the human body, surprisingly evading any immune rejection. Depending on the species, a schistosome pair can produce one egg every 1–10 min; hence the number of eggs and granulomas that accumulate in human tissues over the years is astounding. The pathological process is slow, and the infected person may stay free of serious symptoms for many years and perhaps for life, despite anaemia. However, a small and unpredictable proportion of individuals (generally less than 10%) develop serious problems that range from bloody diarrhoea to portal hypertension and liver cirrhosis, or from haematuria to hydronephrosis. Ectopic localisation of eggs (eg, in the nervous system, genital tract, skin) can cause various symptoms, whereas, for S mansoni, the most common cause of death is the rupture of oesophageal varices after portal hypertension. Bladder cancer associated with S haematobium infection also contributes to the death toll. Two recent papers in Nature Genetics provide new impetus in practical schistosomiasis research. Sergio Verjovski-Almeida